Table 1

Patient characteristics at baseline presentation with CSA

Patient characteristicn=241
Age in years, mean (SD)44.3 (12.9)
Female sex, n (%)187 (77.6)
Family history of RA, n (%)71 (29.5)
Symptom duration in weeks, median (IQR)18.4 (9.7–48.2)
Presence of morning stiffness ≥60 min * †, n (%)80 (33.2)
BMI in kg/m2, median (IQR)26.1 (23.6–29.9)
68-TJC, median * (IQR)6 (3–10)
Current smoker, n (%)54 (22.4)
Autoantibody status
 ACPA-positive (>7 U/mL), n (%)32 (13.3)
 IgM-RF-positive (>3.5 IU/mL), n (%)51 (21.2)
Increased CRP (>10 mg/L), n (%)53 (22.0)
Daily use of NSAIDs, n (%)57 (23.6)
Positive for EULAR definition for arthralgia suspicious for progression to RA,18 n (%)178 (74)
Baseline VAS pain score, median (IQR)5 (3–7)
Baseline HAQ score *
First quartile (n=44)<0.25
Second quartile (n=62)0.25–0.50
Third quartile (n=51)0.63–0.88
Fourth quartile (n=47)≥1.0
  • Symptoms were noted by rheumatologists as reported by the patients.

  • *Missing data were as follows: morning stiffness (27), 68-TJC (4), HAQ score (37).

  • †The presence of symptoms refers to the presence of symptoms at the baseline visit.

  • ACPA, anticitrullinated peptide antibody; BMI, body mass index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor; RA, rheumatoid arthritis; TJC, tender joint count; VAS, Visual Analogue Scale.